HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 23, 20820-20824, June 7, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/23/20820    most recent M203163200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maekawa, A. Articles by Kanaoka, Y. Search for Related Content PubMed PubMed Citation Articles by Maekawa, A. Articles by Kanaoka, Y. Social Bookmarking                      What's this?

Targeted Gene Disruption Reveals the Role of Cysteinyl Leukotriene 1 Receptor in the Enhanced Vascular Permeability of Mice Undergoing Acute Inflammatory Responses^*

Akiko Maekawa, K. Frank Austen, and Yoshihide Kanaoka

From the Department of Medicine, Harvard Medical School, and the Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115

Received for publication, April 2, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The cysteinyl leukotrienes (cysLTs), leukotriene (LT) C₄, LTD₄, and LTE₄, are proinflammatory lipid mediators generated in the mouse by hematopoietic cells such as macrophages and mast cells. There are two mouse receptors for the cysLTs, CysLT₁ receptor (CysLT₁R) and CysLT₂R, which are 38% homologous and are located on mouse chromosomes X and 14, respectively. To clarify the different roles of the CysLT₁R and CysLT₂R in inflammatory responses in vivo, we generated CysLT₁R-deficient mice by targeted gene disruption. These mice developed normally and were fertile. In an intracellular calcium mobilization assay with fura-2 acetoxymethyl ester, peritoneal macrophages from wild-type littermates, which express both CysLT₁R and CysLT₂R, responded substantially to 1 × 10⁶ M LTD₄ and slightly to 1 × 10⁶ M LTC₄, whereas the macrophages from CysLT₁R-deficient mice did not respond to either LTD₄ or LTC₄. Plasma protein extravasation, but not neutrophil infiltration, was significantly reduced in CysLT₁R-deficient mice subjected to zymosan A-induced peritoneal inflammation. Plasma protein extravasation was also significantly diminished in CysLT₁R-deficient mice undergoing IgE-mediated passive cutaneous anaphylaxis as compared with the wild-type mice. Thus, the cysLTs generated in vivo by either monocytes/macrophages or mast cells utilize CysLT₁R for the response of the microvasculature in acute inflammation.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The cysteinyl leukotrienes (cysLTs),¹ leukotriene (LT) C₄, LTD₄, and LTE₄, are proinflammatory lipid mediators (1, 2) that have been implicated in allergic and asthmatic inflammatory responses on the basis of the efficacy of specific intervention with their biosynthetic inhibitors (3) or their receptor blockers (4). LTC₄ synthase (LTC₄S) is the major enzyme responsible for the generation of LTC₄, the parent compound of the cysLTs (5-7). LTC₄S conjugates reduced glutathione to an epoxide metabolite of arachidonic acid, LTA₄, generated by 5-lipoxygenase in the presence of the 5-lipoxygenase-activating protein (8, 9). After carrier-mediated export (10), the sequential cleavage of glutamic acid and glycine from the glutathione moiety of LTC₄ yields LTD₄ and LTE₄ (11, 12), respectively. LTC₄S is expressed in various types of hematopoietic cells such as mast cells, basophils, eosinophils, and monocytes/macrophages. Neutrophils, which lack LTC₄S but express LTA₄ hydrolase (13), make a dihydroxy leukotriene, LTB₄, which has potent chemotactic activity via the LTB₄ receptors, BLT1 and BLT2 (14, 15).

Two types of human receptors for cysLTs, designated cysteinyl leukotriene 1 receptor (CysLT₁R) and CysLT₂R, belonging to the seven-transmembrane, G protein-coupled receptor family, were recently cloned and shown to be 38% homologous (16, 17). The rank order of affinities of the cysLTs for the CysLT₁R and CysLT₂R defined with transfected cells is LTD₄ LTC₄ > LTE₄ LTB₄ and LTD₄ = LTC₄ LTE₄ LTB₄, respectively. The genes for human CysLT₁R and CysLT₂R map to chromosome Xq13-q21 and 13q14, respectively. CysLT₁R is expressed on airway smooth muscle, alveolar macrophages, peripheral blood monocytes, eosinophils (16, 18), and endothelial cells (19). CysLT₂R is expressed on alveolar macrophages, airway smooth muscle, cardiac Purkinje cells, adrenal medulla cells, peripheral blood leukocytes, and brain cells (17). We and others (20-22) have reported that mouse CysLT₁R has two isoforms of cDNA resulting from alternative splicing and that each can function as a receptor for LTD₄ in transfected cells with a ligand preference similar to that of human CysLT₁R. Mouse CysLT₂R was recently cloned and exhibited a ligand profile of LTC₄ = LTD₄ LTE₄ (23, 24). Mouse CysLT₁R and CysLT₂R are 38.9% homologous in amino acid sequence, and their gene loci are mapped to chromosomes X and 14, respectively.

We have previously shown that the increased vascular permeability in zymosan A-induced, monocyte/macrophage-dependent peritoneal inflammation and in IgE-mediated, mast cell-dependent passive cutaneous anaphylaxis is diminished by ~50% in LTC₄S null mice as compared with their wild-type littermates (7). Recently, Shi et al. (25) demonstrated that -glutamyl leukotrienase null mice subjected to zymosan A-induced peritonitis had diminished neutrophil infiltration but intact plasma protein extravasation. In as much as the conversion of LTC₄ to LTD₄ was completely abolished in the peritoneal cavity of the -glutamyl leukotrienase null mice, their findings suggest different roles for LTC₄ and LTD₄ through the same or different receptors. To clarify the role of CysLT₁R relative to CysLT₂R in vivo, we generated CysLT₁R gene-disrupted mice by homologous recombination and examined plasma protein extravasation and neutrophil infiltration in zymosan A-induced peritoneal inflammation and plasma protein extravasation in IgE-mediated passive cutaneous anaphylaxis.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Generation of CysLT₁R Gene-disrupted Mice-- A 7-kb mouse genomic DNA fragment containing exons II-IV of the CysLT₁R gene (20) was subcloned into a pBluescriptII vector (Stratagene, La Jolla, CA). A neo gene cassette from pMC1Neo (Stratagene) was inserted to replace 278 nucleotides of the coding region of the mouse CysLT₁R gene, and the herpes simplex virus thymidine kinase (TK) gene was inserted at the 5'-end of the gene. The resultant targeting vector was linearized and electroporated into a C57BL/6 mouse embryonic stem cell line, ES-MK (26). The embryonic stem cells were selected with G418 (200 µg/ml; Invitrogen) and ganciclovir (2 µM), and homologous recombination was confirmed by Southern blot analysis of ScaI-digested genomic DNA from each embryonic stem cell clone with a ~400-bp 3'-fragment as a probe located outside the targeting vector (Fig. 1A). The embryonic stem cell clones, verified by Southern blot analysis, were microinjected into blastocysts from BALB/c mice, and chimeric males were obtained. Chimeras were bred to C57BL/6 females, and offspring were genotyped by Southern blot analysis of the tail DNA. Heterozygous females were bred to C57BL/6 males to obtain CysLT₁R() C57BL/6 males. These CysLT₁R() or (+) C57BL/6 males were bred to CysLT₁R(+/) C57BL/6 females to obtain CysLT₁R(/) and CysLT₁R(+/+) C57BL/6 females. All experiments except for passive cutaneous anaphylaxis were performed with the F₂ and F₃ generations of CysLT₁R() and CysLT₁R(+) males. Passive cutaneous anaphylaxis was performed with the F₃ generation of CysLT₁R() and CysLT₁R(+) males and F₃ generation of CysLT₁R(/) and CysLT₁R(+/+) females. All animal studies were approved by the Animal Care and Use Committee of the Dana-Farber Cancer Institute.

Northern Blot Analysis-- Total RNA from the lung tissue of CysLT₁R() and CysLT₁R(+) mice was isolated with Tri-Reagent (Sigma). A 20-µg sample of the total RNA was resolved by electrophoresis on a formaldehyde-denatured gel and transferred to a nylon membrane (Pall Corp., Ann Arbor, MI) with 20 × SSC for 24 h. Hybridizations with ³²P-labeled mouse CysLT₁R and glyceraldehyde-3-phosphate dehydrogenase cDNAs were performed as described (20).

Isolation of Peritoneal Macrophages and Calcium Mobilization Assay-- Resident peritoneal macrophages were isolated as described by Qiu et al. (27). Briefly, peritoneal lavage was performed with 10 ml of ice-cold phosphate-buffered saline (PBS). After the lavage fluid was centrifuged at 500 × g for 5 min, the cells were cultured in Petri dishes in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin for 3 h at 37 °C in a humidified atmosphere with 5% CO₂. The non-adherent cells were removed by extensive washing. The adherent cells were collected by dispersion with 0.53 mM EDTA in Hanks' balanced salt solution, re-suspended in Dulbecco's modified Eagle's medium, seeded at 1 × 10⁶ cells onto a glass coverslip (13-mm diameter) in 24-well plates, and cultured for 18 h at 37 °C in a humidified atmosphere with 5% CO₂. The cells were washed twice with Hanks' balanced salt solution containing 1 mM CaCl₂, 1 mM MgCl₂, and 0.1% bovine serum albumin (HBSA²⁺) and incubated with 2.5 µM fura-2 acetoxymethyl ester (Molecular Probes, Eugene, OR) in the presence of 2.5 mM probenecid for 30 min at 37 °C. After the cells were labeled, the coverslips were washed and placed in a diagonal position in a standard 1-cm square methacrylate cuvette containing 2 ml of HBSA²⁺. The cuvette was fitted with a rubber O-ring to position the coverslip just above a magnetic stirring bar. The cells were stimulated with LTB₄, LTC₄, LTD₄, LTE₄ (Cayman Chemical, Ann Arbor, MI) or ATP (Sigma). Fluorescence output was measured with excitation at 340 and 380 nm in a fluorescence spectrophotometer (Hitachi F-4500, Japan), and the relative ratio of fluorescence emitted at 510 nm was recorded. Assays of the cellular response to LTC₄ were performed in the presence of 50 mM serine-borate to inhibit the conversion of LTC₄ to LTD₄ (28).

Zymosan A-induced Peritoneal Inflammation-- Each mouse received an intravenous injection of 0.5% Evans blue dye (10 ml of dye solution/kg of body weight) in PBS immediately before the intraperitoneal injection of 1 ml of zymosan A suspension (1 mg/ml in PBS; Sigma). Mice were euthanized by CO₂ before and 30, 60, 120, and 240 min after the injection of zymosan A and underwent peritoneal lavage with 4 ml of cold PBS. Each peritoneal lavage fluid was divided equally into two tubes, 2 ml for Evans blue dye extravasation and cell counts and 2 ml for the myeloperoxidase (MPO) assay. Cells were sedimented from the lavage fluid by centrifugation at 500 × g for 5 min, and Evans blue dye extravasation was assessed by light spectrophotometry of the supernatants at 610 nm.

The cell pellets were suspended in 100 µl of PBS, and the cells were counted. Cells (2 × 10⁴) were cytospun onto a glass slide, stained with Diff-Quik (Dade Behring, Deerfield, IL), and analyzed for cell types. The total neutrophils in the lavage fluid were calculated from the percentage of the cell type and the total cell count.

The cell pellets from 2 ml of the lavage fluid were suspended in 200 µl of 50 mM potassium phosphate buffer (pH 6.0) with 0.5% hexadecyltrimethylammonium bromide (Sigma), frozen and thawed three times, and sonicated at level 3 for 1 min at 4 °C with a Branson sonifier (Branson Ultrasonics Corp., Danbury, CT). The supernatants of the cell extracts were assayed for MPO as described (29-31). Briefly, 10 µl of diluted samples were added to a 96-well plate. The reaction was initiated by the addition of 190 µl of assay buffer containing 0.167 mg/ml of o-dianosidine (Sigma) and 0.0005% hydrogen peroxide. The rate of change of absorbance at 405 nm was monitored in kinetic mode, and V_max was calculated by a plate reader (Molecular Device, Sunnyvale, CA). Levels of MPO were determined from the calibration curve with human neutrophil MPO (Sigma) as a standard.

The LTC₄S(/) and LTC₄S(+/+) male mice (7) used for the MPO assay and cell counts were from the intercrossing of LTC₄S(+/) males and females that had been backcrossed to the C57BL/6 strain at the N₅ generation.

Passive Cutaneous Anaphylaxis-- Mice received intradermal injections of 25 ng of mouse monoclonal anti-dinitrophenyl (DNP) IgE in 25 µl of saline in the right ear and 25 µl of saline only in the left ear. After 20 h, mice were injected intravenously with 100 µg of DNP-human serum albumin and 1% Evans blue dye in 100 µl of PBS. The mice were euthanized 15 and 30 min after the intravenous injection, and a 6-mm-diameter disc of tissue was obtained from the center of each ear. Each disc was incubated in 200 µl of formamide at 55 °C for 48 h. Extravasation of Evans blue dye was quantitated by spectrophotometric analysis of the formamide extracts at 610 nm, and vascular permeability enhancement was calculated as the net difference between the sensitized and control ears.

Statistical Analysis-- The results of the experiments were expressed as means ± S.E. Student's t test was used for the statistical analysis in cases in which the variance was homogeneous, and Welch's test was used when the variance was heterogeneous. A value of p < 0.05 was considered significant.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Generation of CysLT₁R Gene-disrupted Mice-- The targeting vector was designed so that the neo gene insertion interrupts the coding region that is common to the long and short isoforms of the mouse CysLT₁R gene (Ref. 20; Fig. 1A). Out of 31 embryonic stem cell clones that survived in the presence of G418 and ganciclovir, two were identified as targeted clones by Southern blot analysis for the 4.8-kilobase (kb) band. The embryonic stem cell clones were microinjected into BALB/c-derived blastocysts. Two male chimeric mice (>70% chimerism by coat color) were obtained from each clone and bred to C57BL/6 females. Since the CysLT₁R gene is on the X chromosome, heterozygotes obtained at F₁ generation were female. The heterozygous females were bred to C57BL/6 males to obtain CysLT₁R() males. These CysLT₁R() males were further bred to CysLT₁R(+/) females. Southern blot analysis of ScaI-digested DNA from the progeny demonstrated a 4.8-kb band for the disrupted gene and a 4.0-kb band for the wild-type gene; it also revealed that the ratio was 1:1 for CysLT₁R() and CysLT₁R(+) males and for CysLT₁R(/) and CysLT₁R(+/) females, respectively, as illustrated for one litter (Fig. 1B). The CysLT₁R() males and CysLT₁R(/) females developed normally and were fertile.

View larger version (53K): [in this window] [in a new window]   Fig. 1.   Generation of CysLT1R gene-disrupted mice. A, genomic organization of the mouse CysLT1R gene (upper), structure of the targeting vector (middle), and organization of the putative recombinant CysLT1R allele (lower). Exons II-IV are shown as boxes with the coding regions in black. Restriction enzyme sites include BamHI (B), BglII (Bg), HindIII (H), and ScaI (S). The location of the 400-bp fragment used for Southern blot analysis is shown as a thick line. B, Southern blot analysis of ScaI-digested tail DNAs from the pups of a CysLT1R() male and a CysLT1R(+/) female mouse. C, Northern blot analysis of total RNA from the lung tissue of CysLT1R() and CysLT1R(+) mice. Hybridizations were performed with a 32P-labeled mouse CysLT1R cDNA probe (upper) and then with a 32P-labeled mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe. Molecular size markers are shown at the left.

Since mouse CysLT₁R mRNA is most abundantly expressed in the lung (20), we examined whether homologous recombination by the targeting vector disrupted expression of the CysLT₁R mRNA in the lung. By Northern blot analysis with total RNAs, CysLT₁R mRNA was not detected in CysLT₁R() mice, whereas mRNAs with sizes of 1.4 and 4.0 kb were detected in the lung of CysLT₁R(+) mice (Fig. 1C). This result suggests that the transcript from the recombinant allele is unstable due to displacement of 278 bp of the coding region by the neo gene.

To seek functional evidence of the effect of the CysLT₁R gene disruption, we utilized cysLT-evoked intracellular calcium mobilization in peritoneal macrophages, which expressed both CysLT₁R and CysLT₂R mRNA by reverse transcriptase-PCR (24). The macrophages from wild-type mice showed a rapid intracellular calcium flux in response to stimulation with 1 × 10⁶ M LTD₄ (Fig. 2A), a lesser signal in response to 1 × 10⁶ M LTC₄ (Fig. 2B) or LTE₄ (data not shown), and no response to LTB₄ (data not shown). The preference for LTD₄ is consistent with the ligand profile obtained with Chinese hamster ovary cells stably expressing either the long or the short isoform of the mouse CysLT₁R cDNA (20). In contrast, the macrophages from the CysLT₁R() mice did not show an intracellular calcium flux in response to stimulation with either 1 × 10⁶ M LTD₄ (Fig. 2C) or LTC₄ (Fig. 2D). That macrophages from the CysLT₁R() mice showed a prominent intracellular calcium flux to ATP indicates that the signal transduction mechanism for intracellular calcium flux is intact. These results indicate that CysLT₁R is the major receptor for cysLTs in peritoneal macrophages.

View larger version (20K): [in this window] [in a new window]   Fig. 2.   Intracellular calcium mobilization in peritoneal macrophages from CysLT1R() and CysLT1R(+) mice. Arrows indicate the point of injection of leukotrienes or ATP. A and B, responses to LTD4 (A) and LTC4 (B) in macrophages from CysLT1R(+) mice. C and D, responses to LTD4 and ATP (C) and to LTC4 (D) in macrophages from CysLT1R() mice. Assays of the response to LTC4 were performed in the presence of 50 mM serine-borate. Results are representative of three independent analyses.

That LTD₄ can stimulate rat alveolar macrophages in vitro to increase the mRNA levels of inflammatory cytokines, such as macrophage inflammatory protein (MIP)-1 and tumor necrosis factor (TNF)-, has suggested a priming function of the cysLTs (32). Mouse alveolar (33) and peritoneal (34) macrophages and in vitro cultured mouse (35) and human (36) mast cells are immune effectors that can generate LTC₄. More recently, CysLT₁R expression has been recognized on human alveolar macrophages (16) and human culture-derived mast cells (37) by immunodetection. Moreover, LTC₄ and LTD₄ can stimulate interleukin (IL)-4-primed human mast cells to transcribe and release cytokines, such as IL-5, TNF-, and MIP-1. The CysLT₁R antagonist, MK-571, not only blocks this induction of proinflammatory cytokines by exogenous cysLTs, but also partially inhibits their expression followed by FcRI-mediated activation, revealing that CysLT₁R mediates both innate and adaptive immune responses (38). The close developmental relationship of mast cells and monocytes (39, 40) suggests that CysLT₁R may have a similar effector function for macrophages. Furthermore, CysLT₁R expression can be up-regulated by IL-4 and IL-13 in human peripheral blood monocytes (41) and by IL-5 in eosinophil-differentiated HL-60 cells (42). These findings imply that CysLT₁R may contribute to the cellular phase of a Th2 cell-driven inflammatory response by augmenting production of inflammatory cytokines by immune effector cells.

Role of CysLT₁R in Zymosan A-induced Peritoneal Inflammation-- We examined the role of CysLT₁R in the in vivo monocyte/macrophage-dependent inflammatory response to zymosan A-induced peritoneal inflammation (30, 31). Plasma protein extravasation assessed 30-240 min after zymosan A injection was significantly suppressed in CysLT₁R() mice at all time points as compared with the wild-type mice (Fig. 3A). This result was essentially identical to that obtained with LTC₄S null mice, which lack the capacity to generate cysLTs (7).

View larger version (20K): [in this window] [in a new window]   Fig. 3.   Zymosan A-induced peritoneal inflammation. A, CysLT1R() () and CysLT1R(+) () mice were injected intraperitoneally with 1 ml of zymosan A in PBS (1 mg/ml) immediately after an intravenous injection of 0.5% Evans blue dye. Peritoneal lavage was performed before (0) and 30, 60, 120, and 240 min after zymosan A injection, and the absorbance of the lavage fluid supernatant was measured at 610 nm to quantitate Evans blue dye extravasation. Values at each time point are the mean ± S.E. (n = 3-5 mice). Results are representative of two independent experiments. *, p < 0.001; **, p < 0.005. B, cell pellets at each time point were assayed for total cell counts (upper left) and neutrophil counts (middle left) in each peritoneal lavage fluid and for MPO activity (lower left) shown as MPO units per ml of lavage fluid from CysLT1R() (white bar) and CysLT1R(+) (black bar) mice (left column). A separate experiment is depicted for LTC4S(/) (white bar) and LTC4S(+/+) (black bar) mice (right column). Values are the mean ± S.E. (n = 3 mice). Results are representative of two independent experiments. ND, not detected.

We also examined neutrophil infiltration, which is generally apparent at 120 min and peaks at 240 min after the injection of zymosan A (25, 30, 43). As assessed at these time points with either neutrophil counts or MPO activity, there was no significant difference in neutrophil infiltration between CysLT₁R() and (+) mice (Fig. 3B, left). The findings were similar for the LTC₄S(/) mice (Fig. 3B, right), which do not generate cysLTs but do provide LTB₄ (7). Because of a study showing that plasma protein extravasation in response to zymosan A-induced intraperitoneal inflammation is intact while neutrophil accumulation is attenuated in -glutamyl leukotrienase null mice (25), our results could imply that the LTC₄-CysLT₁R signal is sufficient to increase vascular permeability but not for neutrophil-directed function. However, our additional finding that intraperitoneal neutrophil accumulation is intact in LTC₄S null mice 120 and 240 min after zymosan A injection suggests that cysLTs are not critical to this response in our strains. Our results indicate that a cysLT-CysLT₁R-initiated stimulus plays a major role in the early phase of plasma protein extravasation, but not in the neutrophil infiltration that follows in a later phase of zymosan A-induced peritoneal inflammation.

Role of CysLT₁R in Mast Cell-dependent Passive Cutaneous Anaphylaxis-- Because we previously demonstrated that the edema induced in the ears of LTC₄S null mice by passive cutaneous anaphylaxis is reduced by 50% as compared with their wild-type littermates (7), we next determined whether the CysLT₁R is critical to the alteration of vascular permeability in passive cutaneous anaphylaxis by using CysLT₁R-deficient mice. Preliminary experiments revealed that a change of ear thickness after the antigen challenge is more difficult to detect in C57BL/6 mice than in BALB/c or FVB mice, and therefore we used Evans blue dye extravasation to detect the plasma protein leakage induced by passive cutaneous anaphylaxis (44-46). Evans blue dye extravasation in the ear of CysLT₁R-deficient mice was reduced by ~50% at 15 min and by ~80% at 30 min after antigen challenge as compared with their wild-type littermates (Fig. 4). These results indicate that the increased vascular permeability mediated by cysLTs in passive cutaneous anaphylaxis significantly involves their action through the CysLT₁R.

View larger version (14K): [in this window] [in a new window]   Fig. 4.   Passive cutaneous anaphylaxis in CysLT1R-deficient mice. CysLT1R() male and CysLT1R(/) female mice (white bar) and their wild-type littermates (black bar) received intradermal injections of 25 ng of mouse anti-DNP monoclonal IgE in 25 µl of saline in the right ear and 25 µl of saline only in the left ear. After 20 h, mice were injected intravenously with 100 µg of DNP-human serum albumin and 1% Evans blue dye in 100 µl of PBS. A 6-mm diameter ear disc was isolated 15 and 30 min after the challenge, and Evans blue dye was extracted in 200 µl of formamide at 55 °C for 48 h. Extravasation of Evans blue dye was quantitated by spectrophotometric analysis at 610 nm. The difference between the absorbance of the right and left ear extracts is expressed as mean ± S.E. Values are the mean ± S.E. (n = 3-4 mice). Results are representative of two independent analyses. *, p < 0.01; **, p < 0.005.

We produced CysLT₁R-deficient mice by using C57BL/6 strain-derived embryonic stem cells because the X-linked location of the gene allowed generation of strain purity for F₁ heterozygous females. Another advantage of using the C57BL/6 strain for phenotypic analyses of the gene-disrupted mice could be the recent finding that in this strain the expression levels of CysLT₁R and CysLT₂R are higher than in the 129 strain (24). We then demonstrated that CysLT₁R is the major functional CysLT receptor on peritoneal macrophages by the intracellular calcium mobilization assay. Finally, our in vivo findings with the CysLT₁R gene-disrupted mice reveal a major role for the cysLTs-CysLT₁R signal in innate and adaptive immune responses of vascular permeability enhancement during zymosan A-induced peritoneal inflammation and IgE-mediated, mast cell-dependent local anaphylaxis.

	ACKNOWLEDGEMENTS

We thank Dr. Rudolf Jaenisch (Massachusetts Institute of Technology) for providing C57BL/6 mouse embryonic stem cells, Dr. Arlene Sharpe and Lina Du (Brigham and Women's Hospital) for blastocyst injection of the embryonic stem cell clones, and Dr. Daniel Friend (Brigham and Women's Hospital) for cytological analysis of the peritoneal lavage fluid.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants AI-31599 and AI-36110 and by a grant from the Dana Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Brigham and Women's Hospital, Smith Bldg., Rm. 626C, One Jimmy Fund Way, Boston, MA 02115. Tel.: 617-525-1263; Fax: 617-525-1310; E-mail: ykanaoka@rics.bwh.harvard.edu.

Published, JBC Papers in Press, April 3, 2002, DOI 10.1074/jbc.M203163200

	ABBREVIATIONS

The abbreviations used are: cysLT, cysteinyl leukotriene; LT, leukotriene; LTC₄S, LTC₄ synthase; CysLT₁R, cysteinyl leukotriene 1 receptor; PBS, phosphate-buffered saline; MPO, myeloperoxidase.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

1.	Dahlen, S. E., Hedqvist, P., Hammarstrom, S., and Samuelsson, B. (1980) Nature 288, 484-486[CrossRef][Medline] [Order article via Infotrieve]
2.	Lewis, R. A., Austen, K. F., and Soberman, R. J. (1990) N. Engl. J. Med. 323, 645-655[Medline] [Order article via Infotrieve]
3.	Israel, E., Dermarkarian, R., Rosenberg, M., Sperling, R., Taylor, G., Rubin, P., and Drazen, J. M. (1990) N. Engl. J. Med. 323, 1740-1744[Abstract]
4.	Manning, P. J., Watson, R. M., Margolskee, D. J., Williams, V. C., Schwartz, J. I., and O'Byrne, P. M. (1990) N. Engl. J. Med. 323, 1736-1739[Abstract]
5.	Lam, B. K., Penrose, J. F., Freeman, G. J., and Austen, K. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7663-7667[Abstract/Free Full Text]
6.	Welsch, D. J., Creely, D. P., Hauser, S. D., Mathis, K. J., Krivi, G. G., and Isakson, P. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9745-9749[Abstract/Free Full Text]
7.	Kanaoka, Y., Maekawa, A., Penrose, J. F., Austen, K. F., and Lam, B. K. (2001) J. Biol. Chem. 276, 22608-22613[Abstract/Free Full Text]
8.	Rouzer, C. A., and Samuelsson, B. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 6040-6044[Abstract/Free Full Text]
9.	Miller, D. K., Gillard, J. W., Vickers, P. J., Sadowski, S., LeVeille, C., Mancini, J. A., Charleson, P., Dixon, R. A., Ford-Hutchinson, A. W., Fortin, R., Gauthier, J. Y., Rodkey, J., Rosen, R., Rouzer, C., Sigal, I., Strader, C., and Evans, J. F. (1990) Nature 343, 278-281[CrossRef][Medline] [Order article via Infotrieve]
10.	Lam, B. K., Owen, W. F., Jr., Austen, K. F., and Soberman, R. J. (1989) J. Biol. Chem. 264, 12885-12889[Abstract/Free Full Text]
11.	Anderson, M. E., Allison, R. D., and Meister, A. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 1088-1091[Abstract/Free Full Text]
12.	Lee, C. W., Lewis, R. A., Corey, E. J., and Austen, K. F. (1983) Immunology 48, 27-35[Medline] [Order article via Infotrieve]
13.	Evans, J. F., Dupuis, P., and Ford-Hutchinson, A. W. (1985) Biochim. Biophys. Acta 840, 43-50[Medline] [Order article via Infotrieve]
14.	Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-624[CrossRef][Medline] [Order article via Infotrieve]
15.	Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. (2000) J. Exp. Med. 192, 421-431[Abstract/Free Full Text]
16.	Lynch, K. R., O'Neill, G. P., Liu, Q., Im, D.-S., Sawyer, N., Metters, K. M., Coulombe, N., Abramovitz, M., Figueroa, D. J., Zeng, Z., Connolly, B. M., Bai, C., Austin, C. P., Chateauneuf, A., Stocco, R., Greig, G. M., Kargman, S., Hooks, S. B., Hosfield, E., Williams, D. L., Jr., Ford-Hutchinson, A. W., Caskey, C. T., and Evans, J. F. (1999) Nature 399, 789-793[CrossRef][Medline] [Order article via Infotrieve]
17.	Heise, C. E., O'Dowd, B. F., Figueroa, D. J., Sawyer, N., Nguyen, T., Im, D.-S., Stocco, R., Bellefeuille, J. N., Abramovitz, M., Cheng, R., Williams, D. L., Jr., Zeng, Z., Liu, Q., Ma, L., Clements, M. K., Coulombe, N., Liu, Y., Austin, C. P., George, S. R., O'Neill, G. P., Metters, K. M., Lynch, K. R., and Evans, J. F. (2000) J. Biol. Chem. 275, 30531-30536[Abstract/Free Full Text]
18.	Figueroa, D. J., Breyer, R. M., Defoe, S. K., Kargman, S., Daugherty, B. L., Waldburger, K., Liu, Q., Clements, M., Zeng, Z., O'Neill, G. P., Jones, T. R., Lynch, K. R., Austin, C. P., and Evans, J. F. (2001) Am. J. Respir. Crit. Care Med. 163, 226-233[Abstract/Free Full Text]
19.	Sjöström, M., Jakobsson, P.-J., Heimburger, M., Palmblad, J., and Haeggström, J. Z. (2001) Eur. J. Biochem. 268, 2578-2586[Medline] [Order article via Infotrieve]
20.	Maekawa, A., Kanaoka, Y., Lam, B. K., and Austen, K. F. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2256-2261[Abstract/Free Full Text]
21.	Mollerup, J., Jørgensen, S. T., Hougaard, C., and Hoffmann, E. K. (2001) Biochim. Biophys. Acta 1517, 455-459[Medline] [Order article via Infotrieve]
22.	Martin, V., Sawyer, N., Stocco, R., Unett, D., Lerner, M. R., Abramovitz, M., and Funk, C. D. (2001) Biochem. Pharmacol. 62, 1193-1200[CrossRef][Medline] [Order article via Infotrieve]
23.	Hui, Y., Yang, G., Galczenski, H., Figueroa, D. J., Austin, C. P., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Funk, C. D. (2001) J. Biol. Chem. 276, 47489-47495[Abstract/Free Full Text]
24.	Ogasawara, H., Ishii, S., Yokomizo, T., Kakinuma, T., Komine, M., Tamaki, K., Shimizu, T., and Izumi, T. (2002) J. Biol. Chem. 277, 18763-18768[Abstract/Free Full Text]
25.	Shi, Z.-Z., Han, B., Habib, G. M., Matzuk, M. M., and Lieberman, M. W. (2001) Mol. Cell. Biol. 21, 5389-5395[Abstract/Free Full Text]
26.	Eggan, K., Akutsu, H., Loring, J., Jackson-Grusby, L., Klemm, M., Rideout, W. M., III, Yanagimachi, R., and Jaenisch, R. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6209-6214[Abstract/Free Full Text]
27.	Qiu, Z.-H., Gijòn, M. A., de Carvalho, M. S., Spencer, D. M., and Leslie, C. C. (1998) J. Biol. Chem. 273, 8203-8211[Abstract/Free Full Text]
28.	Tate, S. S., and Meister, A. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 4806-4809[Abstract/Free Full Text]
29.	Bradley, P. P., Priebat, D. A., Christensen, R. D., and Rothstein, G. (1982) J. Invest. Dermatol. 78, 206-209[CrossRef][Medline] [Order article via Infotrieve]
30.	Rao, T. S., Currie, J. L., Shaffer, A. F., and Isakson, P. C. (1994) J. Pharmacol. Exp. Ther. 269, 917-925[Abstract/Free Full Text]
31.	Doherty, N. S., Poubelle, P., Borgeat, P., Beaver, T. H., Westrich, G. L., and Schrader, N. L. (1985) Prostaglandins 30, 769-789[CrossRef][Medline] [Order article via Infotrieve]
32.	Ménard, G., and Bissonnette, E. Y. (2000) Am. J. Respir. Cell Mol. Biol. 23, 572-577[Abstract/Free Full Text]
33.	Rouzer, C. A., Scott, W. A., Hamill, A. L., and Cohn, Z. A. (1982) J. Exp. Med. 155, 720-733[Abstract/Free Full Text]
34.	Rouzer, C. A., Scott, W. A., Cohn, Z. A., Blackburn, P., and Manning, J. M. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 4928-4932[Abstract/Free Full Text]
35.	Razin, E., Mencia-Huerta, J. M., Stevens, R. L., Lewis, R. A., Liu, F. T., Corey, E., and Austen, K. F. (1983) J. Exp. Med. 157, 189-201[Abstract/Free Full Text]
36.	Hsieh, F. H., Lam, B. K., Penrose, J. F., Austen, K. F., and Boyce, J. A. (2001) J. Exp. Med. 193, 123-133[Abstract/Free Full Text]
37.	Mellor, E. A., Maekawa, A., Austen, K. F., and Boyce, J. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7964-7969[Abstract/Free Full Text]
38.	Mellor, E. A., Austen, K. F., and Boyce, J. A. (2002) J. Exp. Med. 195, 583-592[Abstract/Free Full Text]
39.	Kempuraj, D., Saito, H., Kaneko, A., Fukagawa, K., Nakayama, M., Toru, H., Tomikawa, M., Tachimoto, H., Ebisawa, M., Akasawa, A., Miyagi, T., Kimura, H., Nakajima, T., Tsuji, K., and Nakahata, T. (1999) Blood 93, 3338-3346[Abstract/Free Full Text]
40.	Kirshenbaum, A. S., Goff, J. P., Semere, T., Foster, B., Scott, L. M., and Metcalfe, D. D. (1999) Blood 94, 2333-2342[Abstract/Free Full Text]
41.	Thivierge, M., Staková, J., and Rola-Pleszczynski, M. (2001) J. Immunol. 167, 2855-2860[Abstract/Free Full Text]
42.	Thivierge, M., Doty, M., Johnson, J., Staková, J., and Rola-Pleszczynski, M. (2000) J. Immunol. 165, 5221-5226[Abstract/Free Full Text]
43.	Byrum, R. S., Goulet, J. L., Snouwaert, J. N., Griffiths, R. J., and Koller, B. H. (1999) J. Immunol. 163, 6810-6819[Abstract/Free Full Text]
44.	Feinberg, J. G. (1961) Nature 191, 712[Medline] [Order article via Infotrieve]
45.	Inagaki, N., Goto, S., Nagai, H., and Koda, A. (1984) Int. Arch. Allergy Appl. Immunol. 74, 91-92[Medline] [Order article via Infotrieve]
46.	Inagaki, N., Goto, S., Yamasaki, M., Nagai, H., and Koda, A. (1986) Int. Arch. Allergy Appl. Immunol. 81, 58-62[Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. Maekawa, Y. Kanaoka, W. Xing, and K. F. Austen Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors PNAS, October 28, 2008; 105(43): 16695 - 16700. [Abstract] [Full Text] [PDF]

				J. S. Zhou, W. Xing, D. S. Friend, K. F. Austen, and H. R. Katz Mast cell deficiency in KitW-sh mice does not impair antibody-mediated arthritis J. Exp. Med., November 26, 2007; 204(12): 2797 - 2802. [Abstract] [Full Text] [PDF]

				Y. Jiang, L. A. Borrelli, Y. Kanaoka, B. J. Bacskai, and J. A. Boyce CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells Blood, November 1, 2007; 110(9): 3263 - 3270. [Abstract] [Full Text] [PDF]

				K. Tokita, Y. Uchida, and T. Yamamoto Roles of leukocytosis and cysteinyl leukotriene in polymorphonuclear leukocyte-dependent plasma extravasation J. Leukoc. Biol., December 1, 2006; 80(6): 1308 - 1319. [Abstract] [Full Text] [PDF]

				Y. Jiang, Y. Kanaoka, C. Feng, K. Nocka, S. Rao, and J. A. Boyce Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J. Immunol., September 1, 2006; 177(5): 2755 - 2759. [Abstract] [Full Text] [PDF]

				E. Kolaczkowska, A. Scislowska-Czarnecka, M. Chadzinska, B. Plytycz, N. van Rooijen, G. Opdenakker, and B. Arnold Enhanced early vascular permeability in gelatinase B (MMP-9)-deficient mice: putative contribution of COX-1-derived PGE2 of macrophage origin J. Leukoc. Biol., July 1, 2006; 80(1): 125 - 132. [Abstract] [Full Text] [PDF]

				B. A. Olenchock, R. Guo, M. A. Silverman, J. N. Wu, J. H. Carpenter, G. A. Koretzky, and X.-P. Zhong Impaired degranulation but enhanced cytokine production after Fc{varepsilon}RI stimulation of diacylglycerol kinase {zeta}-deficient mast cells J. Exp. Med., June 12, 2006; 203(6): 1471 - 1480. [Abstract] [Full Text] [PDF]

				B. Balestrieri, V. W. Hsu, H. Gilbert, C. C. Leslie, W. K. Han, J. V. Bonventre, and J. P. Arm Group V Secretory Phospholipase A2 Translocates to the Phagosome after Zymosan Stimulation of Mouse Peritoneal Macrophages and Regulates Phagocytosis J. Biol. Chem., March 10, 2006; 281(10): 6691 - 6698. [Abstract] [Full Text] [PDF]

				I. Prinz, C. Gregoire, H. Mollenkopf, E. Aguado, Y. Wang, M. Malissen, S. H.E. Kaufmann, and B. Malissen The Type 1 Cysteinyl Leukotriene Receptor Triggers Calcium Influx and Chemotaxis in Mouse {alpha}{beta}- and {gamma}{delta} Effector T Cells J. Immunol., July 15, 2005; 175(2): 713 - 719. [Abstract] [Full Text] [PDF]

				A. Murai, M. Abe, Y. Hayashi, N. Sakata, T. Katsuragi, and K. Tanaka Comparison Study between the Mechanisms of Allergic Asthma Amelioration by a Cysteinyl-Leukotriene Type 1 Receptor Antagonist Montelukast and Methylprednisolone J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 432 - 440. [Abstract] [Full Text] [PDF]

				M. Peters-Golden, C. Canetti, P. Mancuso, and M. J. Coffey Leukotrienes: Underappreciated Mediators of Innate Immune Responses J. Immunol., January 15, 2005; 174(2): 589 - 594. [Abstract] [Full Text] [PDF]

				Y. Hui, Y. Cheng, I. Smalera, W. Jian, L. Goldhahn, G. A. FitzGerald, and C. D. Funk Directed Vascular Expression of Human Cysteinyl Leukotriene 2 Receptor Modulates Endothelial Permeability and Systemic Blood Pressure Circulation, November 23, 2004; 110(21): 3360 - 3366. [Abstract] [Full Text] [PDF]

				T. C. Beller, A. Maekawa, D. S. Friend, K. F. Austen, and Y. Kanaoka Targeted Gene Disruption Reveals the Role of the Cysteinyl Leukotriene 2 Receptor in Increased Vascular Permeability and in Bleomycin-induced Pulmonary Fibrosis in Mice J. Biol. Chem., October 29, 2004; 279(44): 46129 - 46134. [Abstract] [Full Text] [PDF]

				Y. Kanaoka and J. A. Boyce Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses J. Immunol., August 1, 2004; 173(3): 1503 - 1510. [Abstract] [Full Text] [PDF]

				Y. Satake, B. L. Diaz, B. Balestrieri, B. K. Lam, Y. Kanaoka, M. J. Grusby, and J. P. Arm Role of Group V Phospholipase A2 in Zymosan-induced Eicosanoid Generation and Vascular Permeability Revealed by Targeted Gene Disruption J. Biol. Chem., April 16, 2004; 279(16): 16488 - 16494. [Abstract] [Full Text] [PDF]

T. C. Beller, D. S. Friend, A. Maek